Thursday 7 May, 2026
Introduction: Cytokine release syndrome (CRS) is a systemic inflammatory response triggered by several factors such as infections and certain drugs,…
Read morePoster: Drug/Disease Modelling - Oncology
PREDICTING PROGRESSION-FREE SURVIVAL FOR ABSK-011 (IRPAGRATINIB) IN ADVANCED FGF19+ HCC PATIENTS VIA JOINT MODELING OF TUMOR GROWTH DYNAMICS
Thursday 7 May, 2026
Objectives: FGF19 overexpression (+) occurs in ~30% of hepatocellular carcinoma (HCC) cases and is associated with poor prognosis. The FGF19/FGFR4…
Read moreJOINT MODELING OF TUMOR SIZE AND PROGRESSION-FREE SURVIVAL (PFS) TO SUPPORT PHASE 3 DOSE SELECTION OF ODRONEXTAMAB PLUS CHEMOTHERAPY IN PATIENTS WITH UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Thursday 7 May, 2026
Introduction: In first‑line (1L) DLBCL, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone (R‑CHOP) remains a common treatment. However, up to…
Read moreQuantitative Systems Pharmacology Modeling to Explore Alternative Step-Up Dosing Regimens for Tarlatamab, a DLL3-Targeting T-Cell Engager
Thursday 7 May, 2026
Objectives: Tarlatamab is a DLL3/CD3 bispecific T-cell engager (TCE) recently approved by the FDA for the treatment of extensive-stage small…
Read moreA REPEATED TIME-TO-EVENT ANALYSIS OF LENVATINIB-INDUCED DOSE-LIMITING TOXICITIES IN PATIENTS WITH DIFFERENTIATED THYROID CARCINOMA AND METASTATIC RENAL CELL CARCINOMA
Thursday 7 May, 2026
Objectives: The multikinase inhibitor lenvatinib is poorly tolerated by differentiated thyroid cancer (DTC) and metastatic renal cell carcinoma (mRCC) patients…
Read moreA Scalable, Open-Source PBPK-QSP Framework for Translating the Safety and Efficacy of Bispecifics T-Cell Engager
Thursday 7 May, 2026
Bispecific T-cell engagers (TCEs) offer potent therapeutic benefits, yet their clinical translation is frequently hindered by non-linear pharmacokinetics and severe…
Read moreTMDD modeling for antibodies directed against soluble targets: parameter values for de novo modeling and simulation from experimental data.
Thursday 7 May, 2026
Objectives: Target mediated drug disposition (TMDD) models are widely used to describe monoclonal antibody pharmacokinetics and to predict suppression of…
Read morePopulation pharmacokinetics supports pembrolizumab de-escalation while meeting target exposure in advanced non-small cell lung cancer
Thursday 7 May, 2026
Objectives: Immune checkpoint inhibitors (ICI) such as pembrolizumab have transformed outcomes in advanced non-small cell lung cancer (NSCLC) [1]. Still,…
Read moreCAR-T PERSISTENCE MODELLING: BRIDGING BIOLOGY AND DATA
Thursday 7 May, 2026
Objectives CAR T cell kinetic models are increasingly enriched with biologically structural components that aim to represent processes such as…
Read moreSemi-Mechanistic Population PKPD model of linvoseltamab in Multiple Myeloma
Thursday 7 May, 2026
Introduction: Linvoseltamab is a BCMAxCD3 bispecific antibody approved for triple-class exposed relapsed/refractory (RR) multiple myeloma (MM) after 3 therapies (EU)…
Read more